Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK's Nightstar NASDAQ Listing Backs British Biotech Build-Up Strategy

Executive Summary

The UK developer of gene therapies for inherited eye diseases has listed on NASDAQ, adding to its monetary resources for competing in what is becoming a competitive sector for drug development, and going some way to validating the approach of the UK healthcare investment firm, Syncona, to growing biotech companies.

You may also be interested in...



IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

NuCana's R&D On Agents For Drug-Resistant Cancers Gets IPO Boost

The UK biotech plans to move its early clinical-stage anticancers, designed to improve the efficacy and tolerability of established agents, through its R&D pipeline with the proceeds of its recent US IPO.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel